Talis Biomedical CorporationTalis Biomedical CorporationTalis Biomedical Corporation

Talis Biomedical Corporation

No trades
See on Supercharts
Market capitalization
‪285.14 M‬USD
−34.26USD
‪−62.01 M‬USD
‪412.00 K‬USD
‪1.67 M‬
Beta (1Y)
1.87

About Talis Biomedical Corporation

CEO
Robert J. Kelley
Website
Headquarters
Chicago
Employees (FY)
99
Founded
2013
FIGI
BBG00Y9D99K6
Talis Biomedical Corp. develops and commercializes innovative products that are designed to enable accurate, reliable, low cost and rapid molecular testing for infectious diseases. The company was founded on June 26, 2013 and is headquartered in Chicago, IL.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of TLIS is 9.01 USD — it has increased by 0.11% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Talis Biomedical Corporation stocks are traded under the ticker TLIS.
Talis Biomedical Corporation is going to release the next earnings report on May 7, 2024. Keep track of upcoming events with our Earnings Calendar.
TLIS stock is 2.74% volatile and has beta coefficient of 1.87. Check out the list of the most volatile stocks — is Talis Biomedical Corporation there?
TLIS earnings for the last quarter are −8.27 USD per share, whereas the estimation was −8.21 USD resulting in a −0.76% surprise. The estimated earnings for the next quarter are −7.37 USD per share. See more details about Talis Biomedical Corporation earnings.
Talis Biomedical Corporation revenue for the last quarter amounts to ‪581.00 K‬ USD despite the estimated figure of ‪105.00 K‬ USD. In the next quarter revenue is expected to reach ‪105.00 K‬ USD.
Yes, you can track Talis Biomedical Corporation financials in yearly and quarterly reports right on TradingView.
TLIS stock has risen by 8.40% compared to the previous week, the month change is a 1.10% fall, over the last year Talis Biomedical Corporation has showed a 16.74% increase.
TLIS net income for the last quarter is ‪−13.46 M‬ USD, while the quarter before that showed ‪−15.68 M‬ USD of net income which accounts for 14.17% change. Track more Talis Biomedical Corporation financial stats to get the full picture.
Today Talis Biomedical Corporation has the market capitalization of ‪285.46 M‬, it has increased by 6.26% over the last week.
No, TLIS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, TLIS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Talis Biomedical Corporation stock right from TradingView charts — choose your broker and connect to your account.
TLIS reached its all-time high on Feb 12, 2021 with the price of 508.25 USD, and its all-time low was 4.35 USD and was reached on Oct 31, 2023.
See other stocks reaching their highest and lowest prices.
As of Apr 24, 2024, the company has 99.00 employees. See our rating of the largest employees — is Talis Biomedical Corporation on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Talis Biomedical Corporation technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Talis Biomedical Corporation stock shows the buy signal. See more of Talis Biomedical Corporation technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Talis Biomedical Corporation EBITDA is ‪−63.87 M‬ USD, and current EBITDA margin is ‪−15.78 K‬%. See more stats in Talis Biomedical Corporation financial statements.